Biotie regains rights to develop PDE10 inhibitors for CNS disorders
19-Oct-2010
- Finland
Timo Veromaa, Chief Executive Officer of Biotie commented, "We are excited about PDE10 as a novel target for the treatment of schizophrenia and other disorders of the central nervous system. We have had a succesful research collaboration with Wyeth, and then Pfizer, and together we have generated supportive data for this class. We are now in a position to pursue novel clinical candidates going forward."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.